Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold ELVN on Aug 17, 2026
Data as of Oct 16
▼ SELL$65.3K1,100 shares at $59.35Helen Louise Collins Chief Medical OfficerELVN Enliven Therapeutics, Inc.
- Traded
- Aug 17, 2026
- Disclosed
- Aug 19, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ELVN since disclosure
−37.2%
after the sale
Similar stocks (XLV) since disclosure
+0.6%
XLV — its sector index fund
Change in closing price from Aug 19, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLHelen Louise Collins Chief Medical OfficerELVN Enliven Therapeutics, Inc.$228Kdisclosed Aug 19 · filed 2 days after the trade